BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 18673287)

  • 1. Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.
    Ardelt W; Shogen K; Darzynkiewicz Z
    Curr Pharm Biotechnol; 2008 Jun; 9(3):215-25. PubMed ID: 18673287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytostatic and cytotoxic properties of Amphinase: a novel cytotoxic ribonuclease from Rana pipiens oocytes.
    Ardelt B; Ardelt W; Pozarowski P; Kunicki J; Shogen K; Darzynkiewicz Z
    Cell Cycle; 2007 Dec; 6(24):3097-102. PubMed ID: 18073526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzymatic and structural characterisation of amphinase, a novel cytotoxic ribonuclease from Rana pipiens oocytes.
    Singh UP; Ardelt W; Saxena SK; Holloway DE; Vidunas E; Lee HS; Saxena A; Shogen K; Acharya KR
    J Mol Biol; 2007 Aug; 371(1):93-111. PubMed ID: 17560606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribonucleases as potential modalities in anticancer therapy.
    Ardelt W; Ardelt B; Darzynkiewicz Z
    Eur J Pharmacol; 2009 Dec; 625(1-3):181-9. PubMed ID: 19825371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interdependence between catalytic activity, conformational stability, and cytotoxicity of onconase.
    Schulenburg C; Ardelt B; Ardelt W; Arnold U; Shogen K; Ulbrich-Hofmann R; Darzynkiewicz Z
    Cancer Biol Ther; 2007 Aug; 6(8):1233-9. PubMed ID: 17637563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity.
    Boix E; Wu Y; Vasandani VM; Saxena SK; Ardelt W; Ladner J; Youle RJ
    J Mol Biol; 1996 Apr; 257(5):992-1007. PubMed ID: 8632481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arginine residues are more effective than lysine residues in eliciting the cellular uptake of onconase.
    Sundlass NK; Raines RT
    Biochemistry; 2011 Nov; 50(47):10293-9. PubMed ID: 21980976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Onconase: a ribonuclease with antitumor activity].
    Zwolińska M; Smolewski P
    Postepy Hig Med Dosw (Online); 2010 Feb; 64():58-66. PubMed ID: 20173221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onconase cytotoxicity relies on the distribution of its positive charge.
    Turcotte RF; Lavis LD; Raines RT
    FEBS J; 2009 Jul; 276(14):3846-57. PubMed ID: 19523116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-state thermal unfolding of onconase.
    Casares-Atienza S; Weininger U; Cámara-Artigas A; Balbach J; Garcia-Mira MM
    Biophys Chem; 2011 Dec; 159(2-3):267-74. PubMed ID: 21840114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and characterization of a cytotoxic human-frog chimeric ribonuclease: potential for cancer therapy.
    Newton DL; Xue Y; Boqué L; Wlodawer A; Kung HF; Rybak SM
    Protein Eng; 1997 Apr; 10(4):463-70. PubMed ID: 9194172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Jurkat acute T-lymphocytic leukemia cells by onconase (Ranpirnase) is accompanied by an altered nucleocytoplasmic distribution and reduced expression of transcription factor NF-kappaB.
    Tsai SY; Ardelt B; Hsieh TC; Darzynkiewicz Z; Shogen K; Wu JM
    Int J Oncol; 2004 Dec; 25(6):1745-52. PubMed ID: 15547713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.
    Rybak SM; Pearson JW; Fogler WE; Volker K; Spence SE; Newton DL; Mikulski SM; Ardelt W; Riggs CW; Kung HF; Longo DL
    J Natl Cancer Inst; 1996 Jun; 88(11):747-53. PubMed ID: 8637029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity of an antitumor ribonuclease to Purkinje neurons.
    Newton DL; Walbridge S; Mikulski SM; Ardelt W; Shogen K; Ackerman SJ; Rybak SM; Youle RJ
    J Neurosci; 1994 Feb; 14(2):538-44. PubMed ID: 8301353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onconase dimerization through 3D domain swapping: structural investigations and increase in the apoptotic effect in cancer cells.
    Fagagnini A; Pica A; Fasoli S; Montioli R; Donadelli M; Cordani M; Butturini E; Acquasaliente L; Picone D; Gotte G
    Biochem J; 2017 Nov; 474(22):3767-3781. PubMed ID: 28963346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity.
    Wu Y; Mikulski SM; Ardelt W; Rybak SM; Youle RJ
    J Biol Chem; 1993 May; 268(14):10686-93. PubMed ID: 8486718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of chain termini to the conformational stability and biological activity of onconase.
    Notomista E; Catanzano F; Graziano G; Di Gaetano S; Barone G; Di Donato A
    Biochemistry; 2001 Aug; 40(31):9097-103. PubMed ID: 11478876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of activation-induced apoptosis of lymphocytes by the cytotoxic ribonuclease onconase (Ranpirnase).
    Halicka DH; Pozarowski P; Ita M; Ardelt WJ; Mikulski SM; Shogen K; Darzynkiewicz Z
    Int J Oncol; 2002 Dec; 21(6):1245-50. PubMed ID: 12429974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissimilarity in the reductive unfolding pathways of two ribonuclease homologues.
    Narayan M; Xu G; Ripoll DR; Zhai H; Breuker K; Wanjalla C; Leung HJ; Navon A; Welker E; McLafferty FW; Scheraga HA
    J Mol Biol; 2004 May; 338(4):795-809. PubMed ID: 15099746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies.
    Beck AK; Pass HI; Carbone M; Yang H
    Future Oncol; 2008 Jun; 4(3):341-9. PubMed ID: 18518759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.